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 Highly infectious viral illness
 First pandemic in 1580
 At least 4 pandemics in 19th century
 Three pandemics in the 20th century
– Estimated 50 million deaths worldwide in pandemic of 1918-1919
– Pandemics of 1957 and 1968 of lesser severity
 Most recent pandemic (H1N1) in 2009-2010
 Virus first isolated in 1933
Influenza
 Single-stranded RNA virus
 Orthomyxoviridae family
 3 types:  A,  B,  C
 Subtypes of type A are determined by hemagglutinin and neuraminidase
Influenza Virus
 Type A 
– Moderate to severe illness
– All age groups
– Humans and other animals 
 Type B
– Milder epidemics
– Primarily affects children
– Humans only
 Type C
– Rarely reported in humans
– No epidemics
Influenza Virus Strains
Subtypes of type A determined by hemagglutinin (H) and neuraminidase (N)
Influenza Type A Subtypes
A/California/7/2009 (H1N1)
Virus type   Geographic origin   Strain number   Year of isolation   Virus subtype 
 Antigenic Drift 
– minor change, same subtype 
– caused by point mutations in gene 
– may result in epidemic 
 Antigenic Shift 
– major change, new subtype 
– caused by exchange of gene segments 
– may result in pandemic
Influenza Antigenic Changes 

Influenza Pathogenesis
 Respiratory transmission of virus
 Replication in respiratory epithelium with subsequent destruction of 
cells
 Viremia rarely documented
 Virus shed in respiratory secretions for 5-10 days
Influenza Clinical Features
 Incubation period 2 days (range 1-4 days)
 50% of infected persons develop classic symptoms
 Abrupt onset of fever (usually 101° - 102°F),  myalgia,  sore throat, 
nonproductive cough,  headache
 Pneumonia
– Secondary bacterial pneumonia
– Primary influenza pneumonia
 Reye syndrome
 Myocarditis
 Death reported in <1 per 1,000 cases
Influenza Complications
 Number of influenza-associated deaths varies substantially by year, influenza virus 
type and subtype, and age group
 Annual influenza-associated deaths ranged from 12,000 to 56,000 between 2010 and 
2014, with an average of 23,607 annual deaths
 Persons 65 years of age and older account for 70% to 85% of deaths
 2.7 times more deaths during seasons when A(H3N2) viruses were prominent
Impact of Influenza – Death - United States, 2010-2014
https://www.cdc.gov/flu/about/disease/us_flu-related_deaths.htm, and https://www.cdc.gov/flu/about/disease/65over.htm
 Highest rates of complications and hospitalization among persons 65 years and older, 
young children, and persons of any age with certain underlying medical conditions
 2010-2011 to 2015-2016:  
– Flu-related hospitalizations in the United States ranged from a low of 140,000 
(during 2011-2012) to a high of 710,000 (during 2014-2015). 
– During the 2015-2016 flu season, CDC estimated 310,000 people were hospitalized 
for flu-related illness. 
 About 50% of hospitalizations among persons younger than 65 years of age
 Greater number of hospitalizations during years that A(H3N2) is predominant
Impact of influenza, - Hospitalization – United States - 2010-
2016
 School-age children
– typically have the highest attack rates during community outbreaks of influenza 
– serve as a major source of transmission of influenza within communities 
Influenza Among School-Aged Children 
 Reservoir 
– human, animals (type A only) 
 Transmission 
– respiratory, probably airborne 
 Temporal pattern 
– peak December – March in temperate climate
– may occur earlier or later 
 Communicability 
– 1 day before to 5 days after onset (adults) 
Influenza Epidemiology 
 Clinical and epidemiological characteristics 
 Isolation of influenza virus from clinical specimens (e.g., throat, 
nasopharynx, sputum)
 Significant rise in influenza IgG by serologic assay
Influenza Diagnosis 
Method Types Detected Test Time
Viral tissue cell culture A and B 3-10 days
Rapid cell culture (shell vials; cell mixtures; 
yields live virus) A and B 1-3 days
Immunofluorescence, Direct (DFA) or 
Indirect (IFA) Florescent Antibody Staining A and B 1-4 hours
Reverse Transcriptase Polymerase Chain
Reaction (RT-PCR) and other molecular 
assays [influenza viral RNA or nucleic acid 
detection]
A and B Varies by assay (Generally 60-80 minutes and 4-8 hours)
Rapid Molecular Assay [influenza viral RNA 
or nucleic acid detection] A and B 15 to 30 minutes
Rapid Influenza Diagnostic Tests (antigen 
detection) A and B <15 min.
Influenza Virus Testing Methods
Adapted fromhttps://www.cdc.gov/flu/professionals/diagnosis/overview-testing-methods.htm 

 Monitor prevalence of circulating strains and detect new strains
 Estimate influenza-related morbidity, mortality and economic loss
 Rapidly detect outbreaks
 Assist disease control through rapid preventive action 
Influenza Surveillance
 40%-60% effective among all age groups. 
 74% effective in preventing PICU admissions
 40% effective in preventing hospitalization among adults
 82% effective in preventing ICU admissions 
 80% effective in preventing death among elderly persons 
Inactivated Influenza Vaccine Effectiveness
https://www.cdc.gov/flu/vaccines-work/vaccineeffect.htm?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fflu%2Fabout%2Fqa%2Fvaccineeffect.htm
2019-2020 Influenza Vaccine Recommendations 
Trivalent vaccines:
– An A/Brisbane/2/2018 (H1N1)pdm09-like virus (updated) 
– An A/Kansas/14/2017 (H3N2)-like virus (updated) 
– B/Colorado/06/2017-like virus
Quadrivalent vaccines:
– The above three viruses
– A B/Phuket/3073/2013-like virus
2019-2020 Influenza Vaccine Composition
 IIV = Inactivated influenza vaccine
 LAIV = Live attenuated influenza vaccine
 RIV = Recombinant influenza vaccine
 Prefixes: SD = standard dose
HD = high dose
a = adjuvanted
cc = cell culture-based
 Numeric suffixes (e.g., RIV3, IIV4) indicate trivalent or quadrivalent, 
respectively
Abbreviations
 IIV: 
– Contain inactivated virus, split or subunit
• High Dose or Standard Dose 
• Trivalent or quadrivalent
• Unadjuvanted or adjuvanted
• Egg- or cell culture-based
– Many brands, some approved for those as young as 6 months of age
– Most are intramuscular
 RIV
– Contain recombinant HA
– Egg-free
– quadrivalent
 LAIV
– Live attenuated virus
– Recommended again in 2018-19
Influenza Vaccines
https://www.cdc.gov/mmwr/volumes/67/wr/mm6722a5.htm?s_cid=mm6722a5_w and https://www.cdc.gov/mmwr/volumes/67/rr/pdfs/rr6703a1-H.pdf
Two potential points of confusion
– Four licensed products, but the dose volume differs
• Afluria Quadrivalent: 0.25 mL – newly licensed down to 6 months
• Fluarix Quadrivalent: 0.5 mL
• FluLaval Quadrivalent: 0.5 mL
• Fluzone Quadrivalent: 0.25 mL 
• Fluzone Quadrivalent: 0.5 mL – newly licensed formulation
Dose volume is distinct from number of doses needed
– A child 6 months through 35 months who is recommended for two doses of 
influenza vaccine and receives FluLaval Quadrivalent 0.5 mL still needs the 
second dose of vaccine 4 weeks later
Quick Aside about Influenza Vaccines for 6 Months – 35 
Months of Age
 Routine annual influenza vaccination is recommended for all persons ≥6 
months of age who do not have contraindications
 While vaccination is recommended for everyone in this age group, there 
are some for whom it is particularly important:
– People age ≥6 months who are at high risk of complications and severe illness
– Contacts and caregivers of these people, and of infants under age 6 months 
(because there is no vaccine approved for children this age)
Groups Recommended for Vaccination
 Children age 6 through 59 months and adults age ≥50 years (children under 6 months of age 
are also at high risk, but cannot be vaccinated)
 Persons with chronic pulmonary (including asthma) or cardiovascular (except isolated 
hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including 
diabetes mellitus)
 Immunosuppressed persons
 Women who are or will be pregnant during the influenza season
 Children and adolescents (age 6 months–18 years) who are receiving aspirin therapy and 
who might be at risk for experiencing Reye syndrome after influenza virus infection
 Residents of nursing homes and other long-term care facilities
 American Indians/Alaska Natives
 Persons who are extremely obese (BMI ≥40)
Groups at Increased Risk for Influenza Complications and 
Severe Illness
 Influenza vaccination recommended by ACIP for women who will be 
pregnant during influenza season since 2004
– Increased risk for severe influenza illness in pregnant women, particularly during 
second and third trimesters; 
 Previous language stated pregnant women should receive inactivated 
influenza vaccine (IIV)
 For 2018-19, pregnant women may receive any licensed, recommended, 
age-appropriate influenza vaccine
– IIV or RIV
– LAIV not recommended for pregnant women 
Influenza Vaccination of Pregnant Women
 Vaccination should occur before onset of influenza activity. Health care providers 
should offer vaccination by the end of October, if possible.  
 To avoid missed opportunities for vaccination, providers should offer vaccination 
during routine health care visits and hospitalizations when vaccine is available
 Organized campaigns should occur throughout the season
 Vaccination in July and August might result in suboptimal immunity
Timing of Vaccination
https://www.cdc.gov/mmwr/volumes/68/rr/pdfs/rr6803-H.pdf
Dosing Algorithim for Children 
Age 6 Months Through 8 Years, 
2019–2020
 Similar to past two seasons
 If 2 cumulative doses received prior 
to July 1, 2019, only 1 dose needed 
for 2019-2020
 Only 1 dose needed after the 9th 
birthday
 For children aged 8 years who require 
2 doses of vaccine, both doses should 
be administered even if the child 
turns age 9 years between receipt of 
dose 1 and dose 2. 
 Local reactions (soreness, redness) 
– 15% - 20%
 Fever, malaise, myalgia 
– Less than 1%
Allergic reactions (hives, angioedema, anaphylaxis) 
– Rare 
Guillain-Barré syndrome
Inactivated Influenza Vaccine (IIV) Adverse Reactions
 Children 
– No significant increase in URI symptoms, fever, or other systemic symptoms
– Increased risk of wheezing in children 6-23 months of age
 Adults 
– Significantly increased rate of cough, runny nose, nasal congestion, sore throat, and 
chills reported among vaccine recipients
– No increase in the occurrence of fever
 No serious adverse reactions identified 
Live Attenuated Influenza Vaccine (LAIV) 
Adverse Reactions
• Severe allergic reaction (e.g., anaphylaxis) to a vaccine component or following a prior dose 
of inactivated influenza vaccine
Precaution
 Moderate or severe acute illness
 History of Guillain-Barré syndrome (GBS) within 6 weeks following a previous dose of 
influenza vaccine
Inactivated Influenza Vaccine (IIV) and RIV
Contraindications and Precautions
Contraindication
Contraindications Precautions
• History of severe allergic reaction to any component of the 
vaccine† or after a previous dose of any influenza vaccine 
• Concomitant aspirin or salicylate-containing therapy in 
children and adolescents 
• Children aged 2 through 4 years who have received a 
diagnosis of asthma or whose parents or caregivers report 
that a health care provider has told them during the 
preceding 12 months that their child had wheezing or 
asthma or whose medical record indicates a wheezing 
episode has occurred during the preceding 12 months
• Children and adults who are immunocompromised due to 
any cause (including immunosuppression caused by 
medications or by HIV infection) 
• Close contacts and caregivers of severely 
immunosuppressed persons who require a protected 
environment 
• Pregnancy 
• Receipt of influenza antiviral medication within the 
previous 48 hours 
• Moderate-to-severe acute illness with or without fever
• History of Guillain-Barré syndrome within 6 weeks of 
receipt of influenza vaccine
• Asthma in persons aged ≥5 years
• Other underlying medical conditions that might predispose 
to complications after wild-type influenza infection (e.g., 
chronic pulmonary, cardiovascular [except isolated 
hypertension], renal, hepatic, neurologic, hematologic, or 
metabolic disorders [including diabetes mellitus])
LAIV Contraindications and Precautions
Influenza Vaccination of Persons with Egg Allergy
 Mostly unchanged from last few seasons
 LAIV is an option again this season
 Egg allergic persons can receive any licensed, recommended vaccine that is 
otherwise appropriate (IIV, RIV4, or LAIV4)
 However, RIV not licensed for persons under 18 years of age
 For persons with a history of severe allergic reaction to egg (i.e., any symptom 
other than hives)
 “The selected vaccine should be administered in an inpatient or outpatient medical setting 
(including but not necessarily limited to hospitals, clinics, health departments, and physician 
offices). Vaccine administration should be supervised by a health care provider who is able to 
recognize and manage severe allergic conditions.”
 No specific post-vaccination observation period recommended
 However, per the ACIP General Best Practices guidelines, providers should consider observing 
all recipients of any vaccine for 15 minutes to avoid injury due to syncope
 Amantadine and rimantadine 
– Not recommended because of documented resistance in U.S. influenza isolates 
 Zanamivir, oseltamivir. peramavir, baloxavir 
– Neuraminidase inhibitors
– Effective against influenza A and B
– Oseltamavir and zanamavir approved for prophylaxis
Influenza Antiviral Agents
CDC website on influenza: 
https://www.cdc.gov/flu/index.htm
 ACIP’s Influenza Recommendations web page
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html 
 CDC’s Influenza web page 
www.cdc.gov/flu/index.htm 
 Immunization Action Coalition Influenza web page
www.immunize.org/influenza/ 
 Children’s Hospital of Philadelphia Vaccine Education Center Influenza 
web page
http://www.chop.edu/centers-programs/vaccine-education-center/vaccine-
details/influenza-vaccine#.VgHMa3YpCAU
Influenza Resources


